Cargando…

Oxygen-independent, CDK4/CDK6-dependent degradation of hypoxia-inducible factor-1α takes cancers’ breath away

Detalles Bibliográficos
Autor principal:	Neckers, Len
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730406/ https://www.ncbi.nlm.nih.gov/pubmed/35018216 http://dx.doi.org/10.18632/oncotarget.28166

Ejemplares similares

Take my breath away
por: Thomas, Vinai C, et al.
Publicado: (2017)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Diagnostics to take your breath away
por: Arnold, Carrie
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

Little devil takes your breath away
por: Koole, M. A. C., et al.
Publicado: (2019)

Little devil takes your breath away
por: Koole, M. A. C., et al.
Publicado: (2019)

Fentanyl in an Infant: Taking Our Breath Away
por: Ivanov, Ivan, et al.
Publicado: (2023)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?
por: Becher, Oren J.
Publicado: (2019)

Therapeutic potential of CDK11 in cancer
por: Blazek, Dalibor
Publicado: (2023)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

The role of CDK in the initiation step of DNA replication in eukaryotes
por: Tanaka, Seiji, et al.
Publicado: (2007)

CDK8 as the STAT1 serine 727 kinase?
por: Staab, Julia, et al.
Publicado: (2013)

CDK6 binds and promotes the degradation of the EYA2 protein
por: Kohrt, Dawn, et al.
Publicado: (2014)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

A dual role of Cdk2 in DNA damage response
por: Satyanarayana, Ande, et al.
Publicado: (2009)

CDK4, a new metabolic sensor that antagonizes AMPK
por: Fajas, L., et al.
Publicado: (2018)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022)

Efficient Wnt mediated intestinal hyperproliferation requires the cyclin D2-CDK4/6 complex
por: Myant, Kevin, et al.
Publicado: (2011)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

‘Take my breath away’: arrhythmogenic tricuspid annulus lipomatous infiltration
por: Freitas, Dario, et al.
Publicado: (2020)

CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
por: Mansilla, Sabrina Florencia, et al.
Publicado: (2020)

The role of CDK6 in cancer
por: Nebenfuehr, Sofie, et al.
Publicado: (2020)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

Is CDK9 a promising target for both primary and metastatic osteosarcoma?
por: Qin, Jiang-Jiang
Publicado: (2019)

Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
por: Zhang, Jiawei, et al.
Publicado: (2022)

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
por: Porazzi, Patrizia, et al.
Publicado: (2021)

May an aspirin a day truly take hepatocellular carcinoma away?
por: Giannini, Edoardo G., et al.
Publicado: (2023)

CDK4/6 inhibition protects normal cells against cancer therapy-induced damage
por: Boopathi, Ettickan, et al.
Publicado: (2020)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

CDK4, pRB and E2F1: connected to insulin
por: Fajas, Lluis, et al.
Publicado: (2010)

Gauchos and ochos: a Wee1-Cdk tango regulating mitotic entry
por: Enders, Greg H
Publicado: (2010)

Staging a recovery from mitotic arrest: Unusual ways of Cdk1
por: Surana, Uttam, et al.
Publicado: (2012)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_aj0plf080eclegu880i2hq3ja6